Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane-tazobactam vs Meropenem for ESBL/AmpC Bloodstream Infection
NCT04238390Phase 3Withdrawn
- Sponsor
- The University of Queensland
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of ceftolozane + tazobactam in Bacteremia (2 arms), sponsored by The University of Queensland. Primary endpoint: Mortality rate at 30 days. Planned start Jan 2022; status: withdrawn.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Bacteremia
Beyond the preview
Go deeper on NCT04238390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238390.